Howard, D. R., Munir, T., McParland, L., Rawstron, A. C., Chalmers, A., Gregory, W. M., . . . Hillmen, P. (2017). Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: The Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. Health Technol Assess.
Dyfyniad Arddull ChicagoHoward, Dena R., et al. "Clinical Effectiveness and Cost-effectiveness Results From the Randomised, Phase IIB Trial in Previously Untreated Patients With Chronic Lymphocytic Leukaemia to Compare Fludarabine, Cyclophosphamide and Rituximab With Fludarabine, Cyclophosphamide, Mitoxantrone and Low-dose Rituximab: The Attenuated Dose Rituximab With ChemoTherapy In Chronic Lymphocytic Leukaemia (ARCTIC) Trial." Health Technol Assess 2017.
Dyfyniad MLAHoward, Dena R., et al. "Clinical Effectiveness and Cost-effectiveness Results From the Randomised, Phase IIB Trial in Previously Untreated Patients With Chronic Lymphocytic Leukaemia to Compare Fludarabine, Cyclophosphamide and Rituximab With Fludarabine, Cyclophosphamide, Mitoxantrone and Low-dose Rituximab: The Attenuated Dose Rituximab With ChemoTherapy In Chronic Lymphocytic Leukaemia (ARCTIC) Trial." Health Technol Assess 2017.